World Pharma Today: 2022 biopharma trends roundtable

Scroll Down

The potential of both mRNA technologies and lipid nanoparticle (LNPs) have been highlighted throughout the COVID-19 pandemic. With the upsurge in the mRNA technologies in clinical pipelines globally, 2022 will be a year dominated by mRNA-based products.

In this commentary, Bill Vincent, Founder and Executive Chairman at Genezen, highlights mRNA technologies as the innovation disrupting the biopharmaceutical industry and discusses how LNPs could further impact drug product development in future.

Read the full article here: 2022 innovations to look out for in the pharma arena

You may also be interested in...

4 factors driving the trend towards…

The cell and gene therapy (C&GT) space is expanding rapidly. With...

Read more

Genezen appoints Chief Commercial Officer to…

  Genezen, a cell and gene therapy Contract Development and Manufacturing...

Read more

Downstream Process Development for Lentiviral Vectors…

Lentiviral vectors (LVV) are commonly used as an efficient and safe...

Read more

Stable cell lines vs transient transfection…

The aim of upstream processing in viral vector development and manufacturing...

Read more